Propanc Biopharma Raises $100 Million for Crypto & Cancer Treatment

Propanc Biopharma, an Australian biotech firm, has secured a significant investment of up to $100 million from Hexstone Capital, a crypto-focused family office. This funding will be used to support the development of their lead cancer therapy, PRP, and build a digital asset treasury. The company plans to initiate human trials for PRP in late 2026, targeting patients with metastatic solid tumors and potentially chronic illnesses related to proenzyme mechanisms.